MXPA02012750A - Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion. - Google Patents

Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion.

Info

Publication number
MXPA02012750A
MXPA02012750A MXPA02012750A MXPA02012750A MXPA02012750A MX PA02012750 A MXPA02012750 A MX PA02012750A MX PA02012750 A MXPA02012750 A MX PA02012750A MX PA02012750 A MXPA02012750 A MX PA02012750A MX PA02012750 A MXPA02012750 A MX PA02012750A
Authority
MX
Mexico
Prior art keywords
combination therapy
receptor antagonist
vitronectin receptor
pharmaceuticals
treatment
Prior art date
Application number
MXPA02012750A
Other languages
English (en)
Inventor
John A Barrett
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of MXPA02012750A publication Critical patent/MXPA02012750A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invencion describe kit(s) novedosos que comprenden compuestos de la formula (I): (Q)d-Ln-Ch o (Q)d-Ln-(Ch)d' util para el diagnostico y tratamiento del cancer en terapia de combinacion en un paciente. La presente invencion proporciona compuestos novedosos utiles para el tratamiento de la artritis reumatoide. Los ingredientes farmaceuticos comprenden una porcion objetivo que se enlaza al receptor que se sobreregula durante la angiogenesis, un grupo de enlace opcional, y un radioisotopo terapeuticamente efectivo o porcion formadora de imagen diagnosticamente efectiva.
MXPA02012750A 2000-06-21 2001-06-21 Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion. MXPA02012750A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21321000P 2000-06-21 2000-06-21
PCT/US2001/019793 WO2001097848A2 (en) 2000-06-21 2001-06-21 Vitronectin receptor antagonist pharmaceuticals

Publications (1)

Publication Number Publication Date
MXPA02012750A true MXPA02012750A (es) 2004-07-30

Family

ID=22794168

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012750A MXPA02012750A (es) 2000-06-21 2001-06-21 Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion.

Country Status (12)

Country Link
EP (1) EP1307226B1 (es)
JP (1) JP2004521066A (es)
CN (1) CN1582166A (es)
AT (1) ATE414541T1 (es)
AU (2) AU2001272965C1 (es)
BR (1) BR0111880A (es)
CA (1) CA2412854C (es)
DE (1) DE60136632D1 (es)
IL (1) IL152941A0 (es)
MX (1) MXPA02012750A (es)
NZ (1) NZ522925A (es)
WO (1) WO2001097848A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2001085212A2 (en) * 2000-05-08 2001-11-15 The University Of British Columbia Drug delivery systems for photodynamic therapy
EP1311292A2 (en) * 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2003062198A1 (en) 2002-01-24 2003-07-31 Barnes Jewish Hospital Integrin targeted imaging agents
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
EP1622647B1 (en) * 2003-05-12 2009-11-25 Lantheus Medical Imaging, Inc. Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
JP7034160B2 (ja) 2016-11-28 2022-03-11 バイエル・ファルマ・アクティエンゲゼルシャフト 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物
US11090395B2 (en) * 2018-09-14 2021-08-17 SeeCure Taiwan Co., Ltd. Composition for cross talk between estrogen receptors and cannabinoid receptors
PE20211471A1 (es) 2018-11-23 2021-08-05 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129344A0 (en) * 1996-11-27 2000-02-17 Du Pont Pharm Co Novel integrin receptor antagonists
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
BR9917079A (pt) * 1998-12-18 2001-10-30 Du Pont Pharm Co Compostos antagonistas de receptor devitronectina, kit, composição metalofarmacêuticade diagnóstico ou terapêutica, composição deagente de contraste para ultra-som, composiçãoradiofarmacêutica terapêutica, composiçãofarmacêutica de diagnóstico, método detratamento da artrite reumatóide, do cancêr e darestenose em um paciente, método de formação deimagem da angiogênese terapêutica, do câncer, denovos vasos sanguìneos, da arteriosclerose, darestenose, da isquemia e da lesão por reperfusãodo miocárdio em um paciente
WO2001098294A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
EP1311292A2 (en) * 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
JP2005538030A (ja) * 2000-06-21 2005-12-15 デュポン ファーマシューティカルズ カンパニー 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
AU2002218751A1 (en) * 2000-07-06 2002-01-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions

Also Published As

Publication number Publication date
CN1582166A (zh) 2005-02-16
WO2001097848A3 (en) 2003-03-13
AU2001272965B2 (en) 2005-11-17
NZ522925A (en) 2006-08-31
BR0111880A (pt) 2006-04-25
ATE414541T1 (de) 2008-12-15
AU2001272965C1 (en) 2006-06-29
EP1307226B1 (en) 2008-11-19
CA2412854C (en) 2010-08-17
WO2001097848A2 (en) 2001-12-27
IL152941A0 (en) 2003-06-24
EP1307226A2 (en) 2003-05-07
JP2004521066A (ja) 2004-07-15
AU7296501A (en) 2002-01-02
CA2412854A1 (en) 2001-12-27
DE60136632D1 (de) 2009-01-02

Similar Documents

Publication Publication Date Title
WO2001098294A3 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2001097861A3 (en) Vitronectin receptor antagonist pharmaceuticals
WO2001097860A3 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
WO2000035492A3 (en) Vitronectin receptor antagonist pharmaceuticals
IL173029A0 (en) Imaging agents
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
HUP0003750A2 (hu) Gyógyszerkészítmények
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
DE60001983T2 (de) Bicyclische und tricyclische heteroaromatische verbindungen
AU7296501A (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
NO20031323D0 (no) Peptid-baserte forbindelser
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
YU33203A (sh) Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
DE60001586D1 (de) Diphenyl-piperidin derivate
DK1140203T3 (da) Farmaceutiske præparater som vitronectinreceptorantagonist
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
TR199901761T2 (xx) IL-8 resept�r antagonistleri.
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
WO2000048581A3 (en) Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
DE69514100D1 (de) Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel
TR200103690T2 (tr) IL-8 reseptör antagonistleri
TH13960A (th) สารละลายโซมาโตโพรพินที่เข้ากันได้ในทางชีววิทยา
TH13960EX (th) สารละลายโซมาโตโพรพินที่เข้ากันได้ในทางชีววิทยา

Legal Events

Date Code Title Description
FA Abandonment or withdrawal